SCM
FBLG icon

Sterling Capital Management’s FibroBiologics FBLG Stock Holding History

Sterling Capital Management’s Portfolio FBLG Stock Details FBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1
Closed -$23 – 3416
2025
Q1 		$23 Hold
1
– – ﹤0.01% 3197
2024
Q4 		$52 Hold
1
– – ﹤0.01% 3212
2024
Q3 		$80 Buy
+1
New +$66 ﹤0.01% 3210

Other funds holding FBLG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
YAG
Yorkville Advisors Global Mountainside, New Jersey $155M AUM 58.46% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CFP
Cascade Financial Partners San Diego, California $970M AUM 19.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Cerity Partners
Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sterling Capital Management's FBLG Position: Q2 2025 in Review

Sterling Capital Management sold out of FibroBiologics (FBLG) in Q2 2025, closing a stake of 1 share — an estimated $23 sold.

Sterling Capital Management first reported a position in FBLG in Q3 2024 and held it in 3 quarters. The position peaked at $80 in Q3 2024. 57 funds tracked by Wall St. Rank hold FBLG as of Q2 2025.

  • Sterling Capital Management reported no remaining FibroBiologics position as of Q2 2025 after selling out during the quarter.
  • Sterling Capital Management sold 1 FibroBiologics share in Q2 2025, an estimated $23.
  • Sterling Capital Management first reported a position in FibroBiologics in Q3 2024 and held it in 3 quarters.
  • Sterling Capital Management's FibroBiologics position peaked at $80 in Q3 2024.
  • 57 funds tracked by Wall St. Rank held FibroBiologics as of Q2 2025.

Based on Sterling Capital Management's 13F filing for Q2 2025, filed 6 Aug 2025.